Allogene Therapeutics (ALLO) Projected to Post Earnings on Monday

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) will likely be posting its Q1 2025 quarterly earnings results before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.28) per share and revenue of $0.00 million for the quarter.

Allogene Therapeutics (NASDAQ:ALLO - Get Free Report) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.28) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.06. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Allogene Therapeutics Stock Up 0.6 %

Shares of NASDAQ:ALLO opened at $1.70 on Monday. The company's 50-day moving average price is $1.64 and its 200 day moving average price is $2.01. The company has a market cap of $371.80 million, a PE ratio of -1.09 and a beta of 0.60. Allogene Therapeutics has a fifty-two week low of $1.23 and a fifty-two week high of $3.78.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on ALLO. HC Wainwright cut their price target on Allogene Therapeutics from $9.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, March 19th. Citizens Jmp raised Allogene Therapeutics from a "market perform" rating to an "outperform" rating and set a $5.00 target price on the stock in a research note on Friday, March 14th. Canaccord Genuity Group reissued a "buy" rating and set a $14.00 price target on shares of Allogene Therapeutics in a report on Friday, March 14th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and issued a $10.00 price objective on shares of Allogene Therapeutics in a report on Friday, March 14th. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $9.29.

Insider Buying and Selling

In other Allogene Therapeutics news, CEO David D. Chang sold 46,668 shares of Allogene Therapeutics stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $1.96, for a total value of $91,469.28. Following the transaction, the chief executive officer now owns 5,276,569 shares in the company, valued at approximately $10,342,075.24. The trade was a 0.88 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders have sold 61,757 shares of company stock worth $115,873 in the last ninety days. 24.30% of the stock is currently owned by corporate insiders.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.